![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, March 10, 2020 6:01:04 PM
Recent AIM News
- AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research • GlobeNewswire Inc. • 08/20/2024 12:30:00 PM
- AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/16/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 09:00:56 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/14/2024 11:37:57 AM
- AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast • GlobeNewswire Inc. • 08/13/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 01:41:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 01:39:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 10:05:15 AM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/30/2024 11:14:55 AM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 07/29/2024 01:15:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/26/2024 04:15:08 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/25/2024 09:00:32 PM
- AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy • GlobeNewswire Inc. • 07/24/2024 12:50:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/15/2024 09:19:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 09:00:31 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/11/2024 09:16:04 PM
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment • GlobeNewswire Inc. • 07/03/2024 12:55:00 PM
- AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference • GlobeNewswire Inc. • 06/10/2024 12:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 02:15:24 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 06/03/2024 02:05:35 PM
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series • GlobeNewswire Inc. • 06/03/2024 01:15:00 PM
- AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering • GlobeNewswire Inc. • 05/31/2024 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/31/2024 12:14:18 PM
- AIM ImmunoTech to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 05/20/2024 01:15:00 PM
- AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/16/2024 11:30:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM